Fluoxetine
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fluoxetine and local guidelines before prescribing.
Mechanism
SSRI with a long half-life active metabolite.
Uses
Depression, bulimia nervosa, OCD, in young people (first-line antidepressant).
Dosing
- SSRIs - sertraline, citalopram, escitalopram, fluoxetine, paroxetine | Usual first choice - safer in overdose. Sertraline - preferred after MI or with heart disease. Citalopram/escitalopram - QT prolongation (citalopram max 20 mg over 65). Fluoxetine - long half-life (fewer withdrawal effects), many interactions; first-line in …
Psychiatry: Mood disorders
Side effects
Nausea, insomnia, anxiety, sexual dysfunction, hyponatraemia, bleeding risk; activation.
Interactions
CYP2D6 inhibitor: raises tricyclics, beta-blockers and antipsychotics; MAOIs; warfarin effect rises.
Contraindications and cautions
Mania, uncontrolled epilepsy
Monitoring
Sodium, suicidality in young people
Pregnancy and breastfeeding
Specialist advice
Renal and hepatic impairment
Reduce dose in liver impairment
Overdose and reversal
Supportive; ECG
Special advice
Long half-life means slow washout; fewer discontinuation symptoms; review young patients for suicidal thoughts early.
More from the textbook: uses, cautions and other points
- SSRIs or SNRIs - avoid paroxetine and fluoxetine with tamoxifen.
Endocrinology: Reproductive - Enzyme inhibitors - amiodarone , fluconazole and miconazole (including oral gel ), metronidazole , clarithromycin and erythromycin, ciprofloxacin , co-trimoxazole , allopurinol, cimetidine, SSRIs (fluoxetine, fluvoxamine).
Haematology: Anatomy Physiology and Pharmacology - CYP2D6 inhibitors (fluoxetine, paroxetine) may reduce its effect - use other antidepressants (venlafaxine, citalopram).
Oncology: Principles - Tamoxifen | VTE, endometrial cancer, hot flushes; avoid fluoxetine and paroxetine.
Oncology: Principles - SSRIs or SNRIs (venlafaxine, citalopram - avoid fluoxetine and paroxetine with tamoxifen ).
Oncology: Breast and Gynae Cancers - Tamoxifen | ER-positive breast cancer and prevention; VTE, endometrial cancer, hot flushes; avoid fluoxetine and paroxetine.
Oncology: Breast and Gynae Cancers
Where it is discussed in the book
- Endocrinology: Reproductive (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Oncology: Principles (4 mentions)
- Oncology: Breast and Gynae Cancers (3 mentions)
- Gynaecology: Menstrual Disorders (2 mentions)
- Gynaecology: Fertility Contraception Menopause (2 mentions)
- Rheumatology: Connective tissue diseases (1 mention)
- Psychiatric emergencies (3 mentions)
- Psychiatry: Anxiety, stress and somatic disorders (2 mentions)
- Psychiatry: Safeguarding (3 mentions)
- Psychiatry: Mood disorders (6 mentions)
- Clinical pharmacology and prescribing: Principles of clinical pharmacology (3 mentions)
- Clinical pharmacology and prescribing: Prescribing in special groups (1 mention)
- Clinical Genetics: Prenatal and newborn screening, pharmacogenomics and ethics (2 mentions)
- Biochemistry: Enzymes, vitamins and trace elements (1 mention)